# Pfizer's first-quarter beat of Wall Street expectations on sales and profit.

*biotech · news · 2026-05-07 · The Irish Times*

## Key points

- Eliquis sales grew 13% year-over-year and now represent 15% of Pfizer's total revenue.
- Eliquis, Ibrance, and Prevnar 13 all face key patent expirations within the next two years.
- Vyndamax, recently switched from Vyndaqel, secured patent protection until 2031 after settlements with generics producers.
- Pfizer's first obesity drug from the $10B Metsera acquisition is not expected before 2028.
- Recent launches and acquisitions drove 22% revenue growth, but the upcoming patent cliff remains a serious threat.

**Companies:** Pfizer
**Countries:** United States

[Read the full story on The Irish Times](https://www.irishtimes.com/business/2026/05/07/pfizer-still-trading-on-hope-that-its-pipeline-delivers/)

---

Canonical: https://newsio.io/n/158b3f46-94c1-4020-80a8-72c829fe8ce9/pfizers-first-quarter-beat-of-wall-street-expectations-on-sales-and-profit-sales
Summarized by Newsio from The Irish Times. https://newsio.io/how-it-works